Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Endometrial Carcinoma

NCT00377520 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00377520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00377520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2006
Completion date
September 30, 2008
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of endometrium, cancer of the endometrium, endometrial cancer, endometrial neoplasms, endometrium cancer, genital neoplasms, female, neoplasms, neoplasms by site, neoplasms, endometrial, urogenital neoplasms, uterine neoplasms